KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Deferred Taxes (2016 - 2025)

Amgen has reported Deferred Taxes over the past 13 years, most recently at -$19.0 million for Q4 2025.

  • Quarterly results put Deferred Taxes at -$19.0 million for Q4 2025, up 94.31% from a year ago — trailing twelve months through Dec 2025 was -$721.0 million (up 41.29% YoY), and the annual figure for FY2025 was -$721.0 million, up 41.29%.
  • Deferred Taxes for Q4 2025 was -$19.0 million at Amgen, up from -$30.0 million in the prior quarter.
  • Over the last five years, Deferred Taxes for AMGN hit a ceiling of -$19.0 million in Q4 2025 and a floor of -$623.0 million in Q4 2023.
  • Median Deferred Taxes over the past 5 years was -$250.5 million (2022), compared with a mean of -$243.6 million.
  • Biggest five-year swings in Deferred Taxes: plummeted 718.37% in 2024 and later skyrocketed 94.31% in 2025.
  • Amgen's Deferred Taxes stood at -$189.0 million in 2021, then crashed by 85.71% to -$351.0 million in 2022, then tumbled by 77.49% to -$623.0 million in 2023, then surged by 46.39% to -$334.0 million in 2024, then skyrocketed by 94.31% to -$19.0 million in 2025.
  • The last three reported values for Deferred Taxes were -$19.0 million (Q4 2025), -$30.0 million (Q3 2025), and -$422.0 million (Q2 2025) per Business Quant data.